Ambrosioni E, Brusca A, Caponnetto S, Condorelli M, Corea L, Dal Palù C, Fogari R, Mameli P, Mancia G, Neri Serneri G G
Cattedra di Terapia Medica Sistematica, Università di Bologna.
Minerva Cardioangiol. 1992 Mar;40(3):85-96.
The efficacy and safety of the treatment of arterial hypertension with the ACE-inhibitor quinapril, were evaluated in a multicentre study conducted in Italy. The study, lasting 14 weeks, after a preliminary wash-out period, allowed response-based titration of quinapril dose from 10 mg to 40 mg once a day, with provision to combine additional hydrochlorothiazide (12.5 to 25 mg), in case of persistently high diastolic pressure levels. The efficacy sample included 1267 patients: at therapy week 14, 78.6% of patients were treated with quinapril alone. Global response rate (intent-to-treat) was 83.3%, with a mean reduction of diastolic pressure of 15.8 mmHg (95% confidence interval from 15.5 to 16.2 mmHg). 91 patients reported 126 associated adverse events (7.0%); the most frequently reported event was cough (2.7%). First-dose hypotension was rarely reported (1.3%), even in elderly and diabetic patients.
在意大利进行的一项多中心研究中，评估了血管紧张素转换酶抑制剂喹那普利治疗动脉高血压的疗效和安全性。该研究持续14周，经过初步洗脱期后，允许根据反应将喹那普利剂量从每日10毫克滴定至40毫克，若舒张压持续处于高水平，可加用氢氯噻嗪（12.5至25毫克）。疗效样本包括1267名患者：在治疗第14周时，78.6%的患者仅接受喹那普利治疗。总体缓解率（意向性分析）为83.3%，舒张压平均降低15.8毫米汞柱（95%置信区间为15.5至16.2毫米汞柱）。91名患者报告了126起相关不良事件（7.0%）；最常报告的事件是咳嗽（2.7%）。首剂低血压很少被报告（1.3%），即使在老年和糖尿病患者中也是如此。
